Palvella Therapeutics (NASDAQ:PVLA) Hits New 1-Year High – Time to Buy?

Palvella Therapeutics, Inc. (NASDAQ:PVLA)’s share price reached a new 52-week high during mid-day trading on Tuesday . The stock traded as high as $127.69 and last traded at $124.45, with a volume of 470889 shares. The stock had previously closed at $87.84.

Wall Street Analyst Weigh In

PVLA has been the topic of several recent analyst reports. Craig Hallum initiated coverage on shares of Palvella Therapeutics in a research note on Thursday, December 4th. They set a “buy” rating and a $175.00 price objective on the stock. Chardan Capital boosted their price target on Palvella Therapeutics from $110.00 to $174.00 and gave the company a “buy” rating in a report on Monday, December 15th. TD Cowen reissued a “buy” rating on shares of Palvella Therapeutics in a research note on Monday, February 2nd. Canaccord Genuity Group lifted their price objective on Palvella Therapeutics from $148.00 to $204.00 and gave the company a “buy” rating in a research report on Tuesday, December 16th. Finally, Cantor Fitzgerald upped their target price on Palvella Therapeutics from $120.00 to $200.00 and gave the company an “overweight” rating in a research note on Thursday, November 6th. Two research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $158.69.

Palvella Therapeutics Trading Up 30.9%

The firm has a market capitalization of $1.36 billion, a PE ratio of -43.72 and a beta of -0.16. The firm has a 50-day moving average of $91.58 and a two-hundred day moving average of $77.95.

Insider Activity at Palvella Therapeutics

In other news, COO Kathleen Goin sold 4,302 shares of Palvella Therapeutics stock in a transaction dated Wednesday, January 21st. The stock was sold at an average price of $97.63, for a total value of $420,004.26. The transaction was disclosed in a document filed with the SEC, which is available through this link. 20.50% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the business. Group One Trading LLC grew its stake in Palvella Therapeutics by 151.5% during the fourth quarter. Group One Trading LLC now owns 332 shares of the company’s stock worth $35,000 after buying an additional 200 shares during the period. Price T Rowe Associates Inc. MD lifted its holdings in shares of Palvella Therapeutics by 11.8% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 4,090 shares of the company’s stock valued at $429,000 after acquiring an additional 433 shares in the last quarter. Archer Investment Corp acquired a new stake in Palvella Therapeutics in the 3rd quarter valued at $28,000. Bank of America Corp DE raised its position in Palvella Therapeutics by 12.3% in the third quarter. Bank of America Corp DE now owns 4,689 shares of the company’s stock valued at $294,000 after purchasing an additional 515 shares during the period. Finally, Deutsche Bank AG lifted its stake in shares of Palvella Therapeutics by 8.7% during the fourth quarter. Deutsche Bank AG now owns 6,594 shares of the company’s stock worth $690,000 after purchasing an additional 528 shares in the last quarter. Hedge funds and other institutional investors own 40.11% of the company’s stock.

Palvella Therapeutics Company Profile

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.